I am a physician-scientist dedicated to advancing innovative solutions to complex psychiatric disorders through the careful development of safe and effective pharmaceuticals. I currently work at Boehringer Ingelheim as a patient safety physician and focus primarily on early clinical development (Phase 1/1a) of CNS pharmaceuticals. I have also practiced emergency psychiatry at NewYork-Presbyterian Brooklyn Methodist Hospital since July 2020.

I graduated from Brown University with Honors in Neuroscience. I completed the Medical Scientist Training Program at the State University of New York at Stony Brook, receiving my MD and a PhD in Neuroscience. My dissertation research was on developmental and experiential changes in brain function. I completed psychiatry residency and a child & adolescent psychiatry fellowship at the Icahn School of Medicine at Mount Sinai. I then worked as a research fellow at Columbia University and the New York State Psychiatric Institute and had a private practice focused on treating people with eating disorders.

During training at Mount Sinai, I was selected as a Chief Resident and then as a Chief Fellow. I was appointed as a Leon Levy Fellow in Neuroscience. I was selected as a Laughlin Fellow of the American College of Psychiatrists, after being deemed likely to make a significant contribution to the field of psychiatry. My academic research focused on the neurobiology and treatment of eating disorders. With colleagues, I identified the first genes shown to increase risk for binge-eating disorder and discovered that dysfunctional iron metabolism contributes to this disorder (see BioWorld). My work on mirror exposure therapy was featured in the Wall Street Journal, Psychology Today and Teen Vogue.